Europe Sodium-dependent Glucose Cotransporter 2 Market Size

Europe Sodium-dependent Glucose Cotransporter 2 Market Analysis

The Europe Sodium-dependent Glucose Cotransporter 2 Market size is estimated at USD 1.19 billion in 2023, and is expected to reach USD 1.85 billion by 2028, growing at a CAGR of 9.10% during the forecast period (2023-2028).

The COVID-19 pandemic has substantially impacted the Sodium-dependent Glucose Cotransporter 2 Market. People with diabetes have a weak immune system so, with COVID-19, the immune system gets weaker very fast. People with diabetes have more chances to get into serious complications rather than normal people. The manufacturers of diabetes drugs have taken care during COVID-19 to deliver the medications to diabetes patients with the help of local governments. NovoNordisk stated on their website that “Since the start of COVID-19, our commitment to patients, our employees and the communities where we operate has remained unchanged, we continue to supply our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19.”

SGLT-2 inhibitors also called gliflozins are a class of medicine used to lower high blood glucose levels in people with type 2 diabetes. SGLT-2 drugs have a significant role in managing cardiovascular risk factors including blood pressure, glycemia, weight, cardiac function, and anti‐inflammatory activity. Diabetic drugs have been potential candidates for treating diabetic patients affected by SARS-CoV-2 infection during the COVID-19 pandemic. According to the diabetes category, the estimated cost per hospital admission during the first wave of COVID-19 in Europe ranged from EUR 25,018 for type 2 diabetes patients in good glycemic control to EUR 57,244 for type 1 diabetes patients in poor glycemic control, reflecting a higher risk of intensive care, ventilator support, and a longer hospital stay. The estimated cost for patients without diabetes was EUR 16,993. The expected total direct expenditures for COVID-19 secondary care in Europe were 13.9 billion euros. Diabetes treatment thus accounted for 23.5% of total expenditures.

The European region had witnessed an alarming increase in the prevalence of diabetes, in recent years. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day for maintaining nominal blood glucose levels, such as medications or ingestion of additional carbohydrates by monitoring their blood glucose levels.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.